Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy
This article analyzed China’s revolutionary volume-based purchasing policy, its impact on domestic healthcare companies and related investment...
447 Views
Tigermed IPO: Trading Debut
Hangzhou Tigermed Consulting (H) (3347 HK) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...
416 Views
Tigermed IPO: Valuation Insights
Hangzhou Tigermed Consulting (H) (3347 HK) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...
419 Views
ECM Weekly (26 July 2020) - Li Auto, Ant Financial, Tigermed, Mindspace, Blue Moon
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. The...
383 Views
Tigermed (泰格医疗) A+H: PHIP Updates and Thoughts on Valuation
Hangzhou Tigermed, a leading China-based CRO company, is seeking a USD 1.5 bn H-share listing in Hong Kong. In our previous note, we discussed that...
458 Views